Integrated Diagnostics Holdings PLC (IDHC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integrated Diagnostics Holdings PLC (IDHC) has a cash flow conversion efficiency ratio of 0.051x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($197.02 Million) by net assets ($3.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Integrated Diagnostics Holdings PLC (IDHC) total market value for the company's overall valuation and market capitalisation.
Integrated Diagnostics Holdings PLC - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Integrated Diagnostics Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Integrated Diagnostics Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integrated Diagnostics Holdings PLC ranked by their cash flow conversion efficiency. Explore Integrated Diagnostics Holdings PLC earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cantor Equity Partners II, Inc.
NASDAQ:CEPT
|
N/A |
|
Bravo Mining Corp
V:BRVO
|
-0.005x |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
-0.085x |
|
Anhui Fuhuang Steel Structure Co Ltd
SHE:002743
|
-0.012x |
|
Dk Tech Co.Ltd
KQ:290550
|
0.079x |
|
CLINUVEL PHARMAC.ADRS1
F:UR9A
|
N/A |
|
HD Renewable Energy Co. Ltd.
TW:6873
|
0.070x |
|
ASOS PLC UN.ADR 1 LS-035
F:DYQ0
|
N/A |
Annual Cash Flow Conversion Efficiency for Integrated Diagnostics Holdings PLC (2012–2024)
The table below shows the annual cash flow conversion efficiency of Integrated Diagnostics Holdings PLC from 2012 to 2024. View IDHC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.50 Billion | $1.57 Billion | 0.448x | +155.65% |
| 2023-12-31 | $3.10 Billion | $543.66 Million | 0.175x | +105.54% |
| 2022-12-31 | $2.45 Billion | $208.73 Million | 0.085x | -89.50% |
| 2021-12-31 | $2.79 Billion | $2.27 Billion | 0.812x | +123.33% |
| 2020-12-31 | $2.43 Billion | $882.51 Million | 0.364x | +23.09% |
| 2019-12-31 | $2.36 Billion | $697.41 Million | 0.295x | +27.51% |
| 2018-12-31 | $2.40 Billion | $556.31 Million | 0.232x | +33.04% |
| 2017-12-31 | $2.31 Billion | $403.07 Million | 0.174x | +0.47% |
| 2016-12-31 | $2.30 Billion | $398.66 Million | 0.173x | +77.37% |
| 2015-12-31 | $1.94 Billion | $189.86 Million | 0.098x | -39.86% |
| 2014-12-31 | $1.86 Billion | $301.59 Million | 0.163x | +51.14% |
| 2013-12-31 | $1.95 Billion | $209.29 Million | 0.108x | -65.18% |
| 2012-12-31 | $2.07 Billion | $639.10 Million | 0.309x | -- |
About Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more